Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$4.38 - $18.78 $83,101 - $356,312
-18,973 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$19.0 - $30.95 $221,255 - $360,412
-11,645 Reduced 38.03%
18,973 $372,000
Q3 2021

Nov 15, 2021

BUY
$29.44 - $43.74 $901,393 - $1.34 Million
30,618 New
30,618 $901,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $59.2M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Voloridge Investment Management, LLC Portfolio

Follow Voloridge Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voloridge Investment Management, LLC with notifications on news.